Lexington, MA, – T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the appointments of Marc Jones as Chief Financial Officer and Frédéric Sweeney, Ph.D., as Senior Director, Business Development. “Marc’s and Fred’s combined financial and business development expertise are ideal additions to the T2 Biosystems leadership team as we prepare […]
DiaGenic announces that it has made an investment in the latest technology for analyzing gene expression in blood. The deployment of QuantStudio™ Dx instruments from Life Technologies in the company’s central laboratory will further enhance the regulatory approvability and future clinical utility of DiaGenic’s products in development. DiaGenic’s diagnostic products are based on a laboratory […]
SEATTLE and CHICAGO — NanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced new results from the combined data analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Arimidex, Tamoxifen, Alone or in Combination (ATAC) studies. The results indicated that […]
Omaha, Neb. and Houston, Tex. – Transgenomic, Inc. (OTCBB: TBIO) and ApoCell, Inc. today announced the results of a research collaboration with the University of Texas MD Anderson Cancer Center that coupled ApoCell’s ApoStream™ platform for isolating circulating tumor cells (CTCs) with Transgenomic’s ICE COLD-PCR technology to detect signature mutations in CTCs isolated from the […]
CAMBRIDGE, MA —– Knome Inc., the human genome interpretation company, today announced that its Services division will now provide its clients with advanced HLA typing capabilities as part of its whole genome and exome interpretation offerings. These capabilities will be powered by Omixon’s Targeted HLA Typing technologies. Financial terms of the agreement were not disclosed. […]
PRINCETON, NJ, – GE Healthcare today announced at the 2013 Annual Meeting of the American Society of Clinical Oncology its plans for the commercialization of MultiOmyx™, a ground-breaking new pathology platform, using proprietary methodology to analyze multiple proteins at a single-cell level. Traditional pathology uses multiple slices from paraffin-fixed tumor samples and examines them slide […]
HILDEN, Germany, and MARSEILLE, France, – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced two agreements adding promising new biomarkers involving glioblastoma, lymphoma and other cancers to QIAGEN’s expanding portfolio of potential companion diagnostics that is being developed to help doctors use a patient’s genomic information to guide treatment decisions. In the glioblastoma […]
Austin, Texas – Asuragen Inc., a leading molecular diagnostic company, announced today the launch of its SuraSeq™ Next Generation Sequencing (NGS) Service in its CAP accredited CLIA Laboratory. The SuraSeq™ 500 Clinical Cancer Panel was designed in response to guidelines from the National Comprehensive Cancer Network (NCCN) and will be the first of several targeted […]
SAN DIEGO and ST OUEN L’AUMONE, France, — Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that it, along with its wholly owned subsidiary, Sequenom Center for Molecular Medicine (Sequenom CMM), has entered into technology licensing and marketing agreements with Laboratoire Cerba in France for noninvasive prenatal aneuploidy […]
BUFFALO, N.Y., — Empire Genomics, LLC has been awarded a Phase I SBIR Grant by the National Institute of Health/National Cancer Institute to develop a genomic companion diagnostic test for multiple myeloma (MM). This is the first SBIR grant Empire Genomics has been awarded and it will be funded through October 2013. The Company plans […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
